Is Semax Approved? Russia Yes, EU and US No
Semax is a registered medicine in Russia and unapproved everywhere else — neither the EMA nor the FDA has assessed it. What the research actually shows.
Semax occupies an unusual position. It is not an experimental compound with no clinical history, and it is not an approved medicine in the way that word is normally used here. It is a registered drug — in one country — and unapproved everywhere else.
That single fact explains most of what is confusing about the evidence.
What the molecule is
ACTH is the pituitary hormone that tells the adrenal cortex to release cortisol. It is 39 amino acids long, and different regions of it do different things: the hormonal signalling lives in one part of the sequence, while fragments from another part have effects on the nervous system without the endocrine consequences.
Semax is built from that second region — the ACTH(4-10) fragment — with a Pro-Gly-Pro tail added at the C-terminus. That tail is the engineering. Short peptides are cleared quickly by peptidases; the added residues slow that breakdown and extend how long the molecule survives, which is the same problem, solved a different way, as the modifications discussed in peptide half-life.
The result is a molecule descended from a hormone but without the corticotropic effect of its parent.
What the mechanistic research reports
The preclinical work is reasonably specific about pathways:
| Study | Finding |
|---|---|
| Brain Research, 2006 | Regulation of BDNF and trkB expression in the rat hippocampus |
| Neurochemical Research, 2005 | Activation of dopaminergic and serotoninergic brain systems in rodents |
| Neuropeptides, 2021 | Attenuation of behavioural and neurochemical alterations in a rodent model |
BDNF — brain-derived neurotrophic factor — supports neuronal survival and synaptic plasticity, and trkB is its receptor. A molecule that increases BDNF expression is plausibly interesting for recovery after neural injury, which is the direction the clinical work took.
These are rodent findings. They describe a mechanism; they do not by themselves establish a human effect.
Is Semax approved in the EU or the US?
No. Neither the EMA nor the FDA has assessed it, so it holds no marketing authorisation in either jurisdiction — while being registered and prescribed in Russia. Both statements are true at once, and that is what makes the literature behave the way it does.
Why the clinical literature is hard to read
Semax has been studied clinically in ischaemic stroke, including work assessing its use at different stages of stroke. This is not a marginal indication chosen for convenience; it follows directly from the neurotrophic mechanism.
The difficulty is access and scrutiny. The bulk of this literature is published in Russian-language journals — Zhurnal Nevrologii i Psikhiatrii is the main venue — which has two consequences:
- It has not been through the same volume of international peer review, replication and meta-analysis that a Western-registered indication would attract.
- It is genuinely harder for most readers to evaluate, since abstracts are often the only part available in English.
That is not a claim that the research is poor. It is a statement about how much independent examination it has received, which is a different and verifiable thing.
Neither the EMA nor the FDA has assessed Semax. “Approved in Russia” and “unapproved in the EU” are both true simultaneously, and neither cancels the other. Regulatory approval is jurisdiction-specific, and it is not a global verdict on a molecule.
The July 2026 recommendation
On 24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee recommended that Semax be added to the 503A bulk drug substances list, by 8 votes to 5.
This does not change the sentence above it. Neither the FDA nor the EMA has assessed Semax, and a compounding recommendation is not an assessment of efficacy — the two run on separate tracks and answer different questions. The recommendation is also the first of four stages, with no deadline on the three still to come: what has to happen next.
For a reader in the EU it changes nothing at all, since the 503A mechanism is US law with no European equivalent.
Practical notes
Semax is usually given intranasally rather than by injection, which puts it outside the injection-site concerns that apply to most compounds covered here. What does still apply is stability: peptides in solution degrade on the timescales described in peptide storage, and a nasal solution is a solution. If a vial does have to be made up, the reconstitution calculator converts quantity and volume into a concentration without suggesting an amount.
The Pro-Gly-Pro tail exists to slow enzymatic clearance, so Semax outlasts the bare ACTH(4-10) fragment. By how much is not something we can cite: it is one of the entries in the half-life table where the pharmacokinetic work sits in the same Russian-language literature as the clinical work.
If you are keeping records, the thing worth recording is not only what was taken but what was expected from it. With a compound whose clinical evidence sits behind a language barrier and outside your own regulator’s assessment, the gap between expectation and observation is the only honest measurement available to you.
Frequently asked questions
What is Semax?
A synthetic analogue of the ACTH(4-10) fragment, extended with a Pro-Gly-Pro tail that slows enzymatic breakdown. It was developed in Russia and is usually administered intranasally.
Does Semax act like a hormone?
It is derived from ACTH, but the fragment it is based on lacks the part of the molecule responsible for the hormonal, corticotropic effect. The research interest is in its effects on the central nervous system, not on cortisol release.
Is Semax approved in the EU or the US?
No. It has no marketing authorisation from the EMA or the FDA, and neither agency has assessed it. It is registered and used clinically in Russia, which is why almost all of its clinical literature is Russian-language.
What does the research actually show?
The mechanistic work is largely in rodents — regulation of BDNF and trkB expression in the rat hippocampus, and activation of dopaminergic and serotoninergic systems. The clinical work concerns ischaemic stroke and is published mostly in Russian journals, which limits how widely it has been scrutinised.
Sources
- Brain Research (2006) — Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus
- Neurochemical Research (2005) — Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents
- Zhurnal Nevrologii i Psikhiatrii (2018) — The efficacy of semax in the treatment of patients at different stages of ischemic stroke
- Neuropeptides (2021) — Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations